Citadel Advisors
ORKA

Citadel Advisors’s Oruka Therapeutics ORKA Stock Holding History

Citadel Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-467
Closed -$21.4K – 15461
2024
Q2 		$21.4K Buy
+467
New +$18.6K ﹤0.01% 12571
2024
Q1 		– Sell
-8
Closed -$170 – 15589
2023
Q4 		$170 Hold
8
– – ﹤0.01% 14104
2023
Q3 		$201 Buy
+8
New +$196 ﹤0.01% 14132
2023
Q2 		– Sell
-608
Closed -$14.5K – 15382
2023
Q1 		$14.5K Buy
608
+325
+115% +$8.56K ﹤0.01% 13303
2022
Q4 		$8.02K Sell
283
-1,125
-80% -$28.8K ﹤0.01% 13774
2022
Q3 		$35K Sell
1,408
-2,767
-66% -$78.2K ﹤0.01% 11828
2022
Q2 		$125K Buy
4,175
+3,142
+304% +$88.8K ﹤0.01% 11171
2022
Q1 		$29K Sell
1,033
-692
-40% -$17.1K ﹤0.01% 13122
2021
Q4 		$45K Sell
1,725
-2,175
-56% -$65.5K ﹤0.01% 13309
2021
Q3 		$139K Buy
3,900
+1,858
+91% +$68.7K ﹤0.01% 12469
2021
Q2 		$86K Buy
2,042
+1,109
+119% +$46.3K ﹤0.01% 13035
2021
Q1 		$41K Buy
+933
New +$49K ﹤0.01% 12971

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citadel Advisors's ORKA Position: Q1 2026 in Review

Citadel Advisors increased its Oruka Therapeutics (ORKA) stake by 39% in Q1 2026, buying an estimated $9.78M and bringing the position to 1,007,537 shares worth $49.4M. The position accounts for 0.01% of the portfolio, ranked #1372.

Citadel Advisors first reported a position in ORKA in Q2 2014 and has held it in 24 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Citadel Advisors held 1,007,537 shares of Oruka Therapeutics worth $49.4M as of Q1 2026.
  • Citadel Advisors bought 281,419 Oruka Therapeutics shares in Q1 2026, an estimated $9.78M.
  • Oruka Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1372 holding.
  • Citadel Advisors first reported a position in Oruka Therapeutics in Q2 2014 and has held it in 24 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.